Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Calidi Biotherapeutics, Inc. is participating in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025, in New York [1] - CEO Eric Poma will present on the RedTail platform, which aims to deliver genetic medicines to metastatic sites while evading immune clearance [2] - The RedTail platform is designed to target non-small cell lung cancer, ovarian cancer, and other high unmet medical need tumor types [5] Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted therapies for delivering genetic medicines to distal disease sites [4] - The proprietary RedTail platform utilizes an engineered enveloped oncolytic virus for systemic delivery and targeting of metastatic sites [4] - The company is headquartered in San Diego, California [6]